DE60141829D1 - Behandlung von krebs unter verwendung von organellkristallisierenden verbindungen - Google Patents

Behandlung von krebs unter verwendung von organellkristallisierenden verbindungen

Info

Publication number
DE60141829D1
DE60141829D1 DE60141829T DE60141829T DE60141829D1 DE 60141829 D1 DE60141829 D1 DE 60141829D1 DE 60141829 T DE60141829 T DE 60141829T DE 60141829 T DE60141829 T DE 60141829T DE 60141829 D1 DE60141829 D1 DE 60141829D1
Authority
DE
Germany
Prior art keywords
cocid
cellular
agents
organelle
inducing agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141829T
Other languages
English (en)
Inventor
Qingzhong Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 00111092 external-priority patent/CN1275404A/zh
Priority claimed from US09/663,559 external-priority patent/US6376525B1/en
Priority claimed from US09/687,342 external-priority patent/US6368818B1/en
Priority claimed from CN 00129316 external-priority patent/CN1112447C/zh
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60141829D1 publication Critical patent/DE60141829D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60141829T 2000-04-29 2001-04-27 Behandlung von krebs unter verwendung von organellkristallisierenden verbindungen Expired - Lifetime DE60141829D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN 00111092 CN1275404A (zh) 2000-04-29 2000-04-29 抗癌药物组合物
US09/663,559 US6376525B1 (en) 2000-09-15 2000-09-15 Method and composition for treating cancer using cellular organelle crystallizing agents
US09/687,342 US6368818B1 (en) 2000-10-12 2000-10-12 Methods and compositions for the visualization of cellular organelles using tetrazolium salts
CN 00129316 CN1112447C (zh) 2000-11-13 2000-11-13 一种细胞结构的检测方法
PCT/US2001/013730 WO2001082780A2 (en) 2000-04-29 2001-04-27 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents

Publications (1)

Publication Number Publication Date
DE60141829D1 true DE60141829D1 (de) 2010-05-27

Family

ID=27429887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141829T Expired - Lifetime DE60141829D1 (de) 2000-04-29 2001-04-27 Behandlung von krebs unter verwendung von organellkristallisierenden verbindungen

Country Status (7)

Country Link
EP (1) EP1294922B1 (de)
AT (1) ATE464046T1 (de)
AU (2) AU5738301A (de)
CA (1) CA2407112C (de)
DE (1) DE60141829D1 (de)
IL (2) IL152484A0 (de)
WO (1) WO2001082780A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726009A (en) * 1989-03-20 1998-03-10 Anticancer, Inc. Native-state method and system for determining viability and proliferative capacity of tissues in vitro

Also Published As

Publication number Publication date
WO2001082780A3 (en) 2002-01-24
ATE464046T1 (de) 2010-04-15
WO2001082780A2 (en) 2001-11-08
EP1294922B1 (de) 2010-04-14
CA2407112C (en) 2010-02-09
AU5738301A (en) 2001-11-12
EP1294922A2 (de) 2003-03-26
IL152484A0 (en) 2003-05-29
IL152484A (en) 2009-06-15
AU2001257383B2 (en) 2006-07-06
CA2407112A1 (en) 2001-11-08
EP1294922A4 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
ATE345132T1 (de) 2-ureido-6-heteroaryl-3h-benzoimidazol-4- carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
YU84603A (sh) Novi inhibitori tirozin kinaze
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
MXPA04012965A (es) Inhibidores virales.
MXPA05008126A (es) Inhibidores de girasa y uso de los mismos.
EA200801041A1 (ru) Ингибиторы мек и способы их применения
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
DK1434779T3 (da) Tværbundne glycopeptid-cephalosporinantibiotika
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
DE60141829D1 (de) Behandlung von krebs unter verwendung von organellkristallisierenden verbindungen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
PT1276722E (pt) Inibidores de naftamidina-uroquinase
AR004507A1 (es) Un profarmaco de trovafloxacina, un procedimiento para tratar una in infeccion bacteriana en un mamifero mediante el mismo, un procedimiento paraprepararlo y una composicion farmaceutica que lo comprende
DK1551850T3 (da) 2&#34;-oxo-voruscharin og derivater deraf
DK1146866T3 (da) Metode til behandling af patienter med akne ved administration af cyclisk GMP PDE inhibitator
ECSP034653A (es) Inhibidores de girasa y usos del mismo
TH68410A (th) สารยับยั้งไจเรส และการใช้สารเหล่านี้
TH50261A (th) อนุพันธ์เบนโซ (5,6) ไซโคลเฮพทา (1,2-b) ไพรีดีน เพื่อการยับยั้งฟาร์นีซิลโปรตีนทรานส์เฟอเรส

Legal Events

Date Code Title Description
8364 No opposition during term of opposition